Nektar Therapeutics | Mutual Funds
Mutual Funds that own Nektar Therapeutics
PRIMECAP Odyssey Aggressive Growth Fund
11,934,676
6.92%
-1,144,754
7.04%
06/30/2018
Oppenheimer Global Opportunities Fund
10,594,680
6.14%
-3,605,320
7.53%
03/31/2018
PRIMECAP Odyssey Growth Fund
7,146,656
4.13%
-122,700
3.53%
06/30/2018
Vanguard Health Care Fund
5,364,813
3.11%
4,030,213
0.71%
06/30/2018
Vanguard Total Stock Market Index Fund
4,306,448
2.5%
17,168
0.04%
07/31/2018
Vanguard Mid Cap Index Fund
4,067,907
2.36%
27,617
0.26%
07/31/2018
Fidelity Growth Company Fund
4,064,561
2.36%
-21,367
0.56%
07/31/2018
Fidelity Contrafund
3,530,159
2.04%
-284,453
0.18%
07/31/2018
Vanguard 500 Index Fund
2,918,913
1.69%
6,615
0.04%
07/31/2018
Government Pension Fund - Global (The)
2,424,788
1.41%
-148,490
0.02%
12/31/2017
| Address |
455 Mission Bay Boulevard South
San Francisco California 94158
United States
|
|
Employees
|
- |
| Website |
http://www.nektar.com |
| Updated |
07/08/2019 |
| Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. It operates through the United States and Europe geogrpahical segments. The company was founded in 1990 and is headquartered in San Francisco, CA. |
